Oxford Biomedica PLC Logo

Oxford Biomedica PLC

A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.

OXB | IL

Overview

Corporate Details

ISIN(s):
GB00BDFBVT43
LEI:
213800S1GVQNXQ15K851
Country:
United Kingdom
Address:
WINDRUSH COURT, OX4 6LT OXFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oxford Biomedica PLC (OXB) is a global, innovation-led contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. As a pioneer with over 30 years of experience, the company provides end-to-end services for the development and GMP manufacturing of viral vectors, including lentivirus, adeno-associated virus (AAV), and adenovirus. OXB supports pharmaceutical and biotechnology clients, from early-stage development to commercialization, through its global network of facilities in the UK, US, and France. The company leverages proprietary technology platforms, such as its commercially approved LentiVector™ and inAAVate™ systems, to enable the delivery of life-changing therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-01 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 11.6 KB
2025-09-23 08:00
Earnings Release
Interim Results for 6 months ended 30 June 2025
English 732.3 KB
2025-08-22 16:36
Director's Dealing
PDMR Dealings
English 29.1 KB
2025-08-21 11:24
Major Shareholding Notification
Holding(s) in Company
English 22.2 KB
2025-08-20 08:00
Declaration of Voting Results & Voting Rights Announcements
Admission of Shares and Total Voting Rights
English 10.9 KB
2025-08-15 14:45
Director's Dealing
PDMR Dealings
English 18.8 KB
2025-08-15 08:05
Share Issue/Capital Change
Results of Placing
English 43.5 KB
2025-08-14 18:02
Share Issue/Capital Change
Proposed Placing of New Ordinary Shares
English 168.6 KB
2025-08-01 08:00
Capital/Financing Update
OXB Secures New Loan Facility with Oaktree
English 16.3 KB
2025-08-01 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 10.9 KB
2025-07-28 08:00
Earnings Release
Half Year Trading Update
English 23.8 KB
2025-07-02 08:00
Board/Management Information
Director Declaration
English 9.6 KB
2025-06-23 08:00
M&A Activity
OXB completes acquisition of US subsidiary
English 12.3 KB
2025-06-17 19:00
Director's Dealing
Director/PDMR Shareholding
English 18.8 KB
2025-06-11 08:02
Pre-Annual General Meeting Information
AGM Update
English 12.6 KB

Automate Your Workflow. Get a real-time feed of all Oxford Biomedica PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oxford Biomedica PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland COS
COSMO Pharmaceuticals N.V. Logo
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
Netherlands COPN
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea 060590
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan 4894
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea 365270
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany CVAC
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea 372320
Cyfuse Biomedical K.K. Logo Japan 4892

Talk to a Data Expert

Have a question? We'll get back to you promptly.